Brain metastases are one of the most severe complications of melanoma, the most aggressive type of skin cancer. Researchers at the Institute for ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Scientists from DZNE , University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...
Primary cultured microglia (8 × 104 cells/well; 24 well plate with coverslips) from IRF2BP2KO and littermate control mice were incubated with Flash-Red conjugated microspheres (Bangs Laboratories, Inc ...
According to a new study published in the journal Cellular Signalling, cannabinoids may play a crucial role in preventing and ...
Inhibiting microglia proliferation may thus provide a viable therapeutic ... and then incubated for 48 h at 4°C with primary antibody. Sections were rinsed with 0.1 M PBS 3 × 10 min and incubated in 1 ...
Microglia act as the central nervous system’s primary defense mechanism. In older mice, they were working harder. (ART-ur/Shutterstock) “Aging is the most important risk factor for Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback